GlassScriptPhysician profile
Emily Hilmes
NPI 1992327951
$1,558.71
in general payments reported to CMS, 2019-2025
30 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $38.87 · 2024: $357 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.72 |
| Education | $119.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $177.06 | 2025 | Flexitouch Plus, Nimbl |
| Genentech USA, INC. | $137.58 | 2024-2025 | Tecentriq, Alecensa, Polivy |
| Daiichi Sankyo INC. | $99.99 | 2024 | Enhertu |
| Abbvie INC. | $95.29 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $95.21 | 2024-2025 | Enhertu, Calquence |
| Regeneron Healthcare Solutions, INC. | $88.33 | 2025 | Libtayo |
| Myriad Genetic Laboratories, INC. | $87.79 | 2024-2025 | Myrisk |
| Janssen Biotech, INC. | $81.21 | 2025 | Rybrevant, Talvey, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $77.20 | 2025 | Iclusig, Fruzaqla |
| Incyte Corporation | $76.52 | 2024-2025 | Jakafi, Niktimvo, Monjuvi |
| Novartis Pharmaceuticals Corporation | $63.38 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $52.20 | 2024-2025 | Keytruda, Lynparza |
| Eisai INC. | $44.60 | 2025 | |
| Pfizer INC. | $36.46 | 2025 | |
| Tersera Therapeutics LLC | $35.84 | 2025 | Xermelo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $25.18 | 2025 | |
| Adc Therapeutics America, INC. | $24.99 | 2025 | |
| Alexion Pharmaceuticals, INC. | $24.67 | 2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $23.89 | 2025 | |
| Hologic Sales and Service, LLC | $23.85 | 2024 | Localizer |
| Genzyme Corporation | $23.34 | 2024 | |
| Bioxcel Therapeutics, INC. | $22.82 | 2023 | Igalmi |
| Genmab U.S., INC. | $21.33 | 2025 | Epkinly |
| Exelixis INC. | $19.35 | 2025 | Cabometyx |
| Elucent Medical | $19.10 | 2024 | |
| Geron Corporation | $18.60 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $18.52 | 2025 | |
| Taiho Oncology, INC. | $16.60 | 2025 | |
| Stryker Corporation | $16.05 | 2023 | Spy-Phi System |
| Pharmaand Gmbh | $11.76 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Hilmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.